Detection of Prostate Cancer Proteins in Serum for Cancer Diagnosis with a Blood Test

Abstract (Set) There is a crucial need of discovering novel biomarkers to improve the specificity of clinical diagnosis for prostate cancer. To achieve this goal, quantitative proteomic profiling is required that can be applied in a high-throughput fashion. With the rapid developments of glycopeptide capture and stable isotope labeling technologies, JHU scientists have used mass spectrometry-based proteomic analysis (Matrix-assisted laser desorption/ionization, MALDI TOF) to quantify and identify 92 separate glycoproteins released from cancer tissues in blood. Description (Set) Proposed Use (Set) Prostate cancer develops over a period of several years and is characterized by molecular changes in cancer cells or tissues prior to noticeable symptoms. The proteins from prostate cancer tissues detected in patients? blood can be used to develop a diagnostic blood test to quantify the proteins and detect cancer at an early, more curable stage, in addition to molecularly defining the cancer stage for an accurate prognosis. The biological markers can also be used to monitor the response of a patient?s cancer to surgery, radiation, or chemotherapy. The list of candidate proteins identified in this invention may be used individually or in combination to develop diagnostic assays.

Inventor(s): Zhang, Hui ,Chan, Daniel,Li, Yan,Sokoll, Lori Jean,Zhang, Zhen

Type of Offer: Licensing



« More Medical Patents

---